Valted Seq
Born in South Korea, Dr. Seulki Lee is a world-renowned researcher and nanotechnology expert. Seulki has worked on developing novel therapies for neurodegenerative disorders, cancer, and fibrosis diseases. Dr. Lee has been with Johns Hopkins School of Medicine since 2012, where they are currently an Associate Professor of Radiology.
Before joining Johns Hopkins, Dr. Lee worked at several other companies, including Neuraly, Inc., Precision Molecular, Inc., and Valted Seq, Inc. Seulki has also received multiple awards for their work, including the NRC Associateship from the National Academy of Sciences, the NIH Pathway to Independence Award (K99/R00), Career Development Award and Investigator-Initiated Research Award from the Department of Defense, Thome Memorial Foundation Award and the Maryland Innovation Initiative Award. In 2017, they were selected as a Highly Cited Researchers.
Seulki Lee earned their Doctor of Philosophy (Ph.D.) in Materials Science and Engineering from the Gwangju Institute of Science and Technology.
Some of their coworkers include Mohammad N. Ranjbar - Director, Bioinformatics, Anna Park - Business Development Manager, and Joshua Yang - Head of Business Development. Seulki Lee reports to Nina Urban, Interim CEO.
This person is not in the org chart
This person is not in any offices
Valted Seq
Valted Seq is a discovery stage biopharmaceutical company spearheaded by world-renowned scientists Dr. Ted Dawson and Dr. Valina Dawson of Johns Hopkins University. The company was founded on the belief that a deeper understanding of neurodegenerative pathways is essential to develop precision therapeutics and identify novel biomarkers for some of the most challenging neurodegenerative diseases, including Alzheimer’s and Parkinson’s. Valted Seq is part of the D&D Pharmatech/Neuraly family of companies, which works hand in hand with leading medical research institutions to advance groundbreaking healthcare innovations.